Author:
Breekveldt Emilie C. H.,Toes-Zoutendijk Esther,de Jonge Lucie,Spaander Manon C. W.,Dekker Evelien,van Kemenade Folkert J.,van Vuuren Anneke J.,Ramakers Christian R. B.,Nagtegaal Iris D.,van Leerdam Monique E.,Lansdorp-Vogelaar Iris
Abstract
AbstractBackgroundIn 2014, the national population-based colorectal cancer (CRC) screening program was implemented in the Netherlands. Biennial fecal immunochemical testing (FIT) for hemoglobin (Hb) is used at a cut-off of 47 µg Hb per gram feces. The CRC screening program successfully started, with high participation rates and yield of screening. Now that the program has reached a steady state, there is potential to further optimize the program. Previous studies showed that prior fecal Hb (f-Hb) concentrations just below the FIT cut-off are associated with a higher risk for detection of advanced neoplasia (AN) at subsequent screening rounds. We aim to achieve a better balance between the harms and benefits of CRC screening by offering participants tailored invitation intervals based on prior f-Hb concentrations after negative FIT.MethodsThis mixed-methods study will be performed within the Dutch national CRC screening program and will consist of: (1) a randomized controlled trial (RCT), (2) focus group studies, and (3) decision modelling. The primary outcome is the yield of AN per screened individual in personalized screening vs. uniform screening. Secondary outcomes are perspectives on, acceptability of and adherence to personalized screening, as well as long-term outcomes of personalized vs. uniform screening. The RCT will include 20,000 participants of the Dutch CRC screening program; 10,000 in the intervention and 10,000 in the control arm. The intervention arm will receive a personalized screening interval based on the prior f-Hb concentration (1, 2 or 3 years). The control arm will receive a screening interval according to current practice (2 years). The focus group studies are designed to understand individuals’ perspectives on and acceptability of personalized CRC screening. Results of the RCT will be incorporated into the MISCAN-Colon model to determine long-term benefits, harms, and costs of personalized vs. uniform CRC screening.DiscussionThe aim of this study is to evaluate the yield, feasibility, acceptability and (cost-) effectiveness of personalized CRC screening through tailored invitation intervals based on prior f-Hb concentrations. This knowledge may be of guidance for health policy makers and may provide evidence for implementing personalized CRC screening in The Netherlands and/or other countries using FIT as screening modality.Trial registration:ClinicalTrials.gov, NCT05423886, June 21, 2022,https://clinicaltrials.gov/ct2/show/NCT05423886
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference34 articles.
1. Toes-Zoutendijk E, van Leerdam ME, Dekker E, et al. Real-time monitoring of results during first year of dutch colorectal cancer screening program and optimization by altering fecal immunochemical test cut-off levels. Gastroenterology. 2017;152(4):767-775.e2. https://doi.org/10.1053/j.gastro.2016.11.022.
2. Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, et al. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. Lancet Gastroenterol Hepatol. 2022;7(1):60–8. https://doi.org/10.1016/S2468-1253(21)00368-X.
3. Krul MF, Elferink MAG, Kok NFM, et al. Initial impact of national CRC screening on incidence and advanced colorectal cancer. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.08.046.
4. National Institute for Public Health and the Environment. Monitoring and Evaluation of the Colorectal Cancer Screening Program. Available at: https://www.rivm.nl/en/national-monitoring-of-colorectal-cancer-screening-programme. Last assessed: 22 September 2022.
5. Lieberman DA. Targeted colon cancer screening: a concept whose time has almost come. Am J Gastroenterol. 1992;87(9):1085–93.